We recently published a list of the 10 Best Cancer Stocks to Buy According to Hedge Funds. In this article, we are going to ...

We recently compiled a list of the Jim Cramer Discussed These 10 Stocks, AI Power Demand & Healthcare. In this article, we ...

We recently published a list of Jim Cramer Breaks Silence On DeepSeek AI Sell-Off & Discusses These 12 Stocks.

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

Healthcare product and device company Abbott Laboratories (NYSE:ABT) in Q4 CY2024, with sales up 7.2% year on year to $10.97 ...

Abbott Laboratories (ABT) Q4 CY2024 Highlights: Revenue: $10.97 billion vs analyst estimates of $11.02 billion (7.2% year-on-year growth, in line) Adjusted EPS: $1.34 vs analyst estimates of $1.34 ...

In a report released today, Matt Miksic from Barclays maintained a Buy rating on Abbott Laboratories (ABT – Research Report), with a price ...

In a report released yesterday, David Toung from Argus Research maintained a Buy rating on Abbott Laboratories (ABT – Research Report). The ...

Healthcare product and device company Abbott Laboratories (NYSE:ABT) met Wall Street’s revenue expectations in Q4 CY2024, with sales up 7.2% year on year to $10.97 billion. Its non-GAAP profit ...

Healthcare product and device company Abbott Laboratories (NYSE:ABT) met Wall Street’s revenue expectations in Q4 CY2024, with sales up 7.2% year on year to $10.97 billion. Its non-GAAP profit of ...

Abbott Laboratories appears to be trading close to its estimated fair value The US$133 analyst price target for ABT is 13% less than our estimate of fair value Today we'll do a simple run through of a ...